EUVIMEDEUVIMED entdecken
Vergleichsstudie

Cost per responder analysis of lebrikizumab versus tralokinumab in moderate to severe atopic dermatitis from a United States perspective

Meichen Yu, Jiahao Li, Ruxin Zhang, Bowen Cailin, Guohua Cheng

Expert Review of Pharmacoeconomics & Outcomes Research · 2026

DOI: 10.1080/14737167.2025.2603949 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Expert Review of Pharmacoeconomics & Outcomes Research, 2026. Verfasst von Meichen Yu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Jinan University, Guangzhou, China. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Antibodies, Monoclonal, Dermatologic Agents. Die Arbeit nennt 33 Literaturangaben. Gefördert von: Regulatory Science Research Project of the Greater Bay Area Branch Center for Drug Evaluation and Inspection, National Medical Products Administration.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Lebrikizumab and tralokinumab significantly treat moderate-to-severe atopic dermatitis. Nevertheless, pharmacoeconomic analyses and head-to-head clinical studies for both are lacking. This study aimed to compare the cost per responder of lebrikizumab and tralokinumab in these patients. RESEARCH DESIGN AND METHODS: To indirectly compare the efficacy of lebrikizumab and tralokinumab for in the treatment of moderate-to-severe atopic dermatitis based on published clinical trial data. The number needed to treat and the cost per responder in comparison to a placebo were used to compare the cost-effectiveness of the two therapies. The cost per responder was calculated based on United States drug acquisition costs by multiplying the cost of treatment by the number needed to treat for each therapy. RESULTS: At Week 16, the cost per responder for lebrikizumab and tralokinumab was $67,932 versus $130,655 for EASI-75 and $109,412 versus $176,622 for IGA 0/1.For key secondary endpoints, the cost per responder was consistently lower for lebrikizumab compared to tralokinumab, including 16-week ∆NRS ≥4 ($95,282vs$156,262), and 4-week IGA 0/1 ($68,955vs$151,874). CONCLUSIONS: In comparison to tralokinumab, lebrikizumab had a much lower number needed to treat and cost per responder. These results, based on US pricing, indicate that lebrikizumab appears to be more cost-effective treatment option based on indirect comparisons.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicAntibodies, MonoclonalDermatologic AgentsHumansUnited StatesCost-Benefit AnalysisSeverity of Illness IndexTreatment OutcomeDrug Costs

Stichwörter der Autor:innen

Lebrikizumabatopic dermatitiscost per respondernumber needed to treattralokinumab

Substanzen

Antibodies, MonoclonaltralokinumablebrikizumabDermatologic Agents

Autor:innen und Institutionen

  • Department of Pharmacy, Jinan University, Guangzhou, China.

Förderung

  • Regulatory Science Research Project of the Greater Bay Area Branch Center for Drug Evaluation and Inspection, National Medical Products Administration

Zitieren

APA

Yu, M., Li, J., Zhang, R., Cailin, B., & Cheng, G. (2026). Cost per responder analysis of lebrikizumab versus tralokinumab in moderate to severe atopic dermatitis from a United States perspective. Expert Review of Pharmacoeconomics & Outcomes Research. https://doi.org/10.1080/14737167.2025.2603949

Vancouver

Yu M, Li J, Zhang R, Cailin B, Cheng G. Cost per responder analysis of lebrikizumab versus tralokinumab in moderate to severe atopic dermatitis from a United States perspective. Expert Review of Pharmacoeconomics & Outcomes Research. 2026. doi:10.1080/14737167.2025.2603949

BibTeX
@article{Yu2026,
  author = {Yu, Meichen and Li, Jiahao and Zhang, Ruxin and Cailin, Bowen and Cheng, Guohua},
  title = {Cost per responder analysis of lebrikizumab versus tralokinumab in moderate to severe atopic dermatitis from a United States perspective},
  journal = {Expert Review of Pharmacoeconomics & Outcomes Research},
  year = {2026},
  doi = {10.1080/14737167.2025.2603949}
}
Kostenlos starten →